BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 25432811)

  • 21.
    Hungria EM; Bührer-Sékula S; Oliveira RM; Aderaldo LC; Pontes MAA; Cruz R; de Gonçalves HS; Penna MLF; Penna GO; Stefani MMA
    Front Immunol; 2018; 9():915. PubMed ID: 29867930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Field experiences with therapy protocols in leprosy].
    Pattyn SR
    Verh K Acad Geneeskd Belg; 1983; 45(3):303-14. PubMed ID: 6364614
    [No Abstract]   [Full Text] [Related]  

  • 23. A man with facial changes.
    Mirfazaelian H; Eilami O; Afzalimoghadam M; Daneshbod Y
    Br J Hosp Med (Lond); 2014 Nov; 75(11):656. PubMed ID: 25383440
    [No Abstract]   [Full Text] [Related]  

  • 24. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
    Deps P; Guerra P; Nasser S; Simon M
    Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe type 1 upgrading leprosy reaction in a renal transplant recipient: a paradoxical manifestation associated with deficiency of antigen-specific regulatory T-cells?
    Vieira AP; Trindade MAB; de Paula FJ; Sakai-Valente NY; Duarte AJDS; Lemos FBC; Benard G
    BMC Infect Dis; 2017 Apr; 17(1):305. PubMed ID: 28438129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dapsone Resistance in Leprosy Patients Originally from American Samoa, United States, 2010-2012.
    Williams DL; Araujo S; Stryjewska BM; Scollard D
    Emerg Infect Dis; 2018 Aug; 24(8):1584-1585. PubMed ID: 30016255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined regimens of one year duration in the treatment of multibacillary leprosy--I. Combined regimens with rifampicin administered during one year.
    Pattyn SR; Bourland J; Grillone S; Groenen G; Ghys P
    Lepr Rev; 1989 Jun; 60(2):109-17. PubMed ID: 2671559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up.
    Ganapati R; Revankar CR; Pai VV; Kingsley S
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):308-9. PubMed ID: 10575413
    [No Abstract]   [Full Text] [Related]  

  • 30. Study of multidrug therapy in paucibacillary leprosy.
    Kar PK; Sohi AS
    J Indian Med Assoc; 1989 Feb; 87(2):34-6. PubMed ID: 2674283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-dose treatment for paucibacillary leprosy; field implications.
    Revankar CR; Pai VV; Samy MS; Ganapati R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):312-4. PubMed ID: 10575415
    [No Abstract]   [Full Text] [Related]  

  • 32. The future of leprosy in the Dominican Republic: experience with multidrug therapy.
    Martinez Cruz D
    Lepr Rev; 1986; 57 Suppl 3():127-33. PubMed ID: 3573953
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug resistance patterns in Mycobacterium leprae isolates from relapsed leprosy patients attending The Leprosy Mission (TLM) Hospitals in India.
    Lavania M; Jadhav RS; Chaitanya VS; Turankar R; Selvasekhar A; Das L; Darlong F; Hambroom UK; Kumar S; Sengupta U
    Lepr Rev; 2014 Sep; 85(3):177-85. PubMed ID: 25509718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single dose multidrug therapy for single lesion paucibacillry leprosy.
    Salafia A
    Indian J Lepr; 1998; 70(2):216-9; author reply 219-21. PubMed ID: 9724861
    [No Abstract]   [Full Text] [Related]  

  • 35. Multidrug therapy--the pathway for global leprosy elimination.
    al-Qubati Y; al-Kubati AS
    Indian J Lepr; 2000; 72(4):477-90. PubMed ID: 11212482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Painless Nodular Rash in a Young Man.
    Bass M; Foster K; Studdiford J
    Am Fam Physician; 2017 Aug; 96(3):189-190. PubMed ID: 28762689
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical pilot study: Clarithromycin efficacy in multibacillary leprosy therapy.
    Gunawan H; Sasmojo M; Putri HE; Avriyanti E; Hindritiani R; Suwarsa O
    Int J Mycobacteriol; 2018; 7(2):152-155. PubMed ID: 29900892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide.
    Winsley BE; McDougall AC; Brown KE
    Int J Lepr Other Mycobact Dis; 1983 Dec; 51(4):592-4. PubMed ID: 6686974
    [No Abstract]   [Full Text] [Related]  

  • 39. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
    Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
    Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should large lesions of leprosy be considered as "multibacillary" for treatment purposes even if the total number of lesions is less than five?
    Kumarasinghe SP; Kumarasinghe MP
    Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):173-4. PubMed ID: 15301583
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.